Bayer announced on Monday that its experimental drug elinzanetant had met its primary and secondary endpoints in two Phase 3 studies for the treatment of menopausal symptoms.

According to the German group, both trials showed a 'statistically significant' reduction versus placebo in the frequency and severity of vasomotor symptoms in postmenopausal women.

The secondary endpoints, which included a reduction in symptoms from the first week of treatment and an improvement in sleep quality, were also achieved.

The two studies, named 'Oasis 1' and 'Oasis 2', enrolled 396 and 400 post-menopausal women aged 40 to 65 respectively, at 184 research centers in 15 countries.

Bayer shares, listed on the Frankfurt Stock Exchange, rose by a limited 0.1% following this announcement.

Copyright (c) 2024 CercleFinance.com. All rights reserved.